AbbVie (ABBV) Profit After Tax (2012 - 2026)

AbbVie (ABBV) has reported Profit After Tax for 15 consecutive years, with $3.6 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Profit After Tax rose 284.27% year-over-year to $3.6 billion in Q2 2026; TTM through Jun 2026 was $6.3 billion, a 67.47% increase from a year earlier, with the FY2025 full-year figure at $4.2 billion, down 1.24% from the prior year.
• Profit After Tax was $3.6 billion for Q2 2026 at AbbVie, up from $697.0 million in the prior quarter.
• Over five years, Profit After Tax peaked at $4.5 billion in Q1 2022 and troughed at -$22.0 million in Q4 2024.
• A 5-year average of $1.6 billion and a median of $1.4 billion in 2024 frame the typical range for Profit After Tax.
• Across the five-year window, Profit After Tax slumped 102.68% in 2024 and surged 8354.55% in 2025, its largest moves.
• Over 5 years, Profit After Tax stood at $2.5 billion in 2022, then sank by 66.76% to $822.0 million in 2023, then plunged by 102.68% to -$22.0 million in 2024, then surged by 8354.55% to $1.8 billion in 2025, then jumped by 99.12% to $3.6 billion in 2026.
• The last three Profit After Tax figures came in at $3.6 billion (Q2 2026), $697.0 million (Q1 2026), and $1.8 billion (Q4 2025), per Business Quant data.